Literature DB >> 16778311

Visceral leishmaniasis in the New World & Africa.

Jonathan Berman1.   

Abstract

Visceral leishmaniasis in the New World, primarily found in northeastern Brazil, is caused by Leishmania chagasi. Compared to India, unusual features of Brazilian disease are the large number of asymptomatic infections versus symptomatic infections, and the apparent change from a zoonotic disease to a partially anthroponotic one. Visceral disease in Africa is caused by L. donovani as in India, but disease differs from that in India in being zoonotic rather than anthroponotic, and in the large numbers of patients who acquire post-kala-azar dermal leishmaniasis.

Entities:  

Mesh:

Year:  2006        PMID: 16778311

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  18 in total

1.  Tetraazamacrocyclic derivatives and their metal complexes as antileishmanial leads.

Authors:  Timothy J Hubin; Ashlie N Walker; Dustin J Davilla; TaRynn N Carder Freeman; Brittany M Epley; Travis R Hasley; Prince N A Amoyaw; Surendra Jain; Stephen J Archibald; Timothy J Prior; Jeanette A Krause; Allen G Oliver; Babu L Tekwani; M Omar F Khan
Journal:  Polyhedron       Date:  2019-02-23       Impact factor: 3.052

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Serine protease activities in Leishmania (Leishmania) chagasi promastigotes.

Authors:  Raquel Elisa da Silva-López; Tatiana Resende dos Santos; José Andrés Morgado-Díaz; Marcelo Neves Tanaka; Salvatore Giovanni de Simone
Journal:  Parasitol Res       Date:  2010-07-29       Impact factor: 2.289

4.  DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis.

Authors:  Jinlei He; Fan Huang; Jianhui Zhang; Han Chen; Qiwei Chen; Junrong Zhang; Jiao Li; Zhiwan Zheng; Dali Chen; Jianping Chen
Journal:  Immunology       Date:  2018-10-24       Impact factor: 7.397

5.  Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid.

Authors:  Néstor M Carballeira; Michelle M Cartagena; Christopher Fernández Prada; Celia Fernández Rubio; Rafael Balaña-Fouce
Journal:  Lipids       Date:  2009-09-30       Impact factor: 1.880

6.  Serological and molecular survey of Leishmania parasites in apparently healthy dogs in the West Bank, Palestine.

Authors:  Omar Hamarsheh; Abedalmajeed Nasereddin; Safa Damaj; Samir Sawalha; Hanan Al-Jawabreh; Kifaya Azmi; Ahmad Amro; Suheir Ereqat; Ziad Abdeen; Amer Al-Jawabreh
Journal:  Parasit Vectors       Date:  2012-08-31       Impact factor: 3.876

Review 7.  Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.

Authors:  Gláucia F Cota; Marcos R de Sousa; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07

Review 8.  Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities.

Authors:  Lyn-Marie Birkholtz; Marni Williams; Jandeli Niemand; Abraham I Louw; Lo Persson; Olle Heby
Journal:  Biochem J       Date:  2011-09-01       Impact factor: 3.857

9.  Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania.

Authors:  Nicolas Collin; Regis Gomes; Clarissa Teixeira; Lily Cheng; Andre Laughinghouse; Jerrold M Ward; Dia-Eldin Elnaiem; Laurent Fischer; Jesus G Valenzuela; Shaden Kamhawi
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

10.  Moving from unsequenced to sequenced genome: reanalysis of the proteome of Leishmania donovani.

Authors:  Raja Sekhar Nirujogi; Harsh Pawar; Santosh Renuse; Praveen Kumar; Sandip Chavan; Gajanan Sathe; Jyoti Sharma; Sweta Khobragade; Janhavee Pande; Bhakti Modak; T S Keshava Prasad; H C Harsha; Milind S Patole; Akhilesh Pandey
Journal:  J Proteomics       Date:  2013-05-09       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.